Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — ASCO 2018
8 slides from Daiichi Sankyo's conference presentation, May 16, 2018
Slide 1: ASCO 2018 Summary of Presentation
ASCO 2018 Summary of Presentation May 16, 2018
Slide 2: ASCO: Accepted Presentations
ASCO: Accepted Presentations Oral presentations DS-8201 Pexidartinib Poster discussions U3-1402 Quizartinib DS-3032 Poster presentations Trial-in-Progress DS-8201 U3-1402 DS-1062
Slide 3: Important and Interesting ADC Presentations
Important and Interesting ADC Presentations DS-8201 Ph1 study (multiple tumor) update Abstract No: 2501 Oral presentation on June 1st, 2:45 PM – 5:45 PM U3-1402 Ph1 study (breast cancer) update Abstract No: 2512 Poster discussion on June 4th, 3:00 PM – 4:15 PM Results will be updated at
Slide 4: ASCO Presentations: DS-8201
ASCO Presentations: DS-8201 DSI Compound Presentation Tumor Type Lead Author Title Session Type Abstract No: 2501 Trastuzumab deruxtecan Session Name: (DS-8201a) in subjects Developmental with HER2-expressing Therapeutics- Clinical DS-8201 Oral HER2-positive Hiroji Iwata solid tumors: Long-term Phar
Slide 5: ASCO Presentations: ADC Franchise
ASCO Presentations: ADC Franchise DSI Compound Presentation Tumor Type Lead Author Title Session Type Abstract No: 2512 Session Name: Developmental Therapeutics-Clinical Pharmacology and Single Agent Activity of Experimental Therapeutics U3-1402, a HER3- Poster Metastatic breast Takahiro Targeting A
Slide 6: ASCO Presentations: AML Franchise
ASCO Presentations: AML Franchise DSI Presentation Tumor Type Lead Author Title Session Compound Type Abstract No.: 7017 Session Name: Hematologic Post hoc exploratory Malignancies-Leukemia, analysis of two phase 2 Myelodysplastic Syndromes, trials of quizartinib and Allotransplant FLT3-ITD- monothe
Slide 7: ASCO Presentations: Breakthrough Science
ASCO Presentations: Breakthrough Science DSI Compound Presentation Type Tumor Type Lead Author Title Session Final results of ENLIVEN: a global, Abstract No: double-blind, 11502 randomized, Session Name: Pexidartinib Tenosynovial giant- placebo-controlled, Sarcoma Oral Presentation William D. Tap Da
Slide 8: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp